BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KT-621 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of KT-621\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07823205-1407@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:KT-621: Phase 1 readout est. (NCT07823205)
DESCRIPTION:KT-621\, phase 1.\nStudy: A Study to Evaluate Different Oral Fo
 rmulations of KT-621\nEstimated primary completion: April 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/kt-621#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07823205
URL:https://assetmemo.bio/drug/kt-621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217015-1407@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:KT-621: Phase 2 readout est. (NCT07217015)
DESCRIPTION:KT-621\, phase 2\, Atopic Dermatitis.\nStudy: A Study of KT-621
  Administered Orally to Participants With Moderate to Severe Atopic Dermat
 itis\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/kt-621#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07217015
URL:https://assetmemo.bio/drug/kt-621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323654-1407@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:KT-621: Phase 2 readout est. (NCT07323654)
DESCRIPTION:KT-621\, phase 2\, Asthma.\nStudy: A Study of KT-621 Administer
 ed Orally to Adult Participants With Moderate to Severe Eosinophilic Asthm
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/kt-621#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07323654
URL:https://assetmemo.bio/drug/kt-621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677059-1407@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:KT-621: Phase 2 readout est. (NCT07677059)
DESCRIPTION:KT-621\, phase 2\, Asthma.\nStudy: A Long-term Study of KT-621 
 Administered Orally to Participants With Asthma Previously Enrolled in a K
 T-621 Asthma Study\nEstimated primary completion: December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/kt-621#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07677059
URL:https://assetmemo.bio/drug/kt-621#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
